These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2993609)

  • 1. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors.
    Portoghese PS; Larson DL; Yim CB; Sayre LM; Ronsisvalle G; Lipkowski AW; Takemori AE; Rice KC; Tam SW
    J Med Chem; 1985 Sep; 28(9):1140-1. PubMed ID: 2993609
    [No Abstract]   [Full Text] [Related]  

  • 2. 10-Ketonaltrexone and 10-ketooxymorphone.
    Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
    J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation.
    Koman A; Einarsson M; Terenius L
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Dec; 331(4):355-8. PubMed ID: 2419770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist and antagonist bivalent ligands as receptor probes.
    Portoghese PS; Ronsisvalle G; Larson DL; Yim CB; Sayre LM; Takemori AE
    Life Sci; 1982 Sep 20-27; 31(12-13):1283-6. PubMed ID: 6292615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking.
    Hazum E; Chang KJ; Leighton HJ; Lever OW; Cuatrecasas P
    Biochem Biophys Res Commun; 1982 Jan; 104(1):347-53. PubMed ID: 6176227
    [No Abstract]   [Full Text] [Related]  

  • 6. Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine.
    Portoghese PS; Nagase H; Takemori AE
    J Med Chem; 1988 Jul; 31(7):1344-7. PubMed ID: 2838632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers.
    Portoghese PS; Ronsisvalle G; Larson DL; Takemori AE
    J Med Chem; 1986 Sep; 29(9):1650-3. PubMed ID: 3018242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
    Sayre LM; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1984 Oct; 27(10):1325-35. PubMed ID: 6090663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
    Caruso TP; Takemori AE; Larson DL; Portoghese PS
    Science; 1979 Apr; 204(4390):316-8. PubMed ID: 86208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 11. Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
    Galetta S; Hahn EF; Nishimura S; Pasternak GW
    Life Sci; 1987 Aug; 41(6):783-7. PubMed ID: 2441221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
    Fang X; Larson DL; Portoghese PS
    J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine.
    Ward SJ; LoPresti D; James DW
    J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity of dynorphin for kappa opioid receptors.
    James IF; Chavkin C; Goldstein A
    Life Sci; 1982 Sep 20-27; 31(12-13):1331-4. PubMed ID: 6128656
    [No Abstract]   [Full Text] [Related]  

  • 15. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
    Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
    Kshirsagar TA; Fang X; Portoghese PS
    J Med Chem; 1998 Jul; 41(14):2657-60. PubMed ID: 9651172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
    Schmidhammer H; Leander JD; Mayer-Valkanover K; Nussbaumer C; Schmidt C; Schoepp DD; Schratz A; Walla-Kugler M
    Prog Clin Biol Res; 1990; 328():41-4. PubMed ID: 2154800
    [No Abstract]   [Full Text] [Related]  

  • 18. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
    Takemori AE; Larson DL; Portoghese PS
    Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
    Gao P; Larson DL; Portoghese PS
    J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.